• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The management of hypercholesterolaemia in patients with coronary artery disease referred for coronary angiography.

作者信息

Saia F, Chua T P, Fox K M

机构信息

Department of Cardiology, Royal Brompton Hospital, London, UK.

出版信息

Int J Cardiol. 1998 Dec 31;67(3):247-9. doi: 10.1016/s0167-5273(98)00317-9.

DOI:10.1016/s0167-5273(98)00317-9
PMID:9894706
Abstract

There are clear benefits in treating hypercholesterolaemia in patients with ischaemic heart disease, especially those with previous myocardial infarction. Following publication of trial evidence and treatment guidelines for hypercholesterolaemia, we investigated the current practice of the management of hypercholesterolaemia in patients with coronary artery disease referred for coronary angiography by general physicians. We prospectively reviewed 156 consecutive patients (117 men; mean age 61.5+/-9.6 [S.D.] years) with a history of angina pectoris who attended the day case unit for coronary angiography in a 10 week period. Nearly a tenth of these patients had not been screened for hypercholesterolaemia in this study. Of those patients with a cholesterol level > or =5.5 mmol/l, almost a quarter were not on a statin or any other cholesterol-lowering therapy. Continued effort should be given to the screening and effective management of hypercholesterolaemia in patients with coronary artery disease.

摘要

相似文献

1
The management of hypercholesterolaemia in patients with coronary artery disease referred for coronary angiography.
Int J Cardiol. 1998 Dec 31;67(3):247-9. doi: 10.1016/s0167-5273(98)00317-9.
2
Cholesterol lowering with statins reduces exercise-induced myocardial ischemia in hypercholesterolemic patients with coronary artery disease.他汀类药物降低胆固醇可减轻冠状动脉疾病的高胆固醇血症患者运动诱发的心肌缺血。
Am J Cardiol. 2001 Nov 15;88(10):1134-8. doi: 10.1016/s0002-9149(01)02048-3.
3
Pravastatin and risk factor modification in patients with moderate primary hypercholesterolaemia.普伐他汀与中度原发性高胆固醇血症患者的危险因素改善
N Z Med J. 1996 Aug 23;109(1028):319-22.
4
Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.他汀类药物与贝特类药物联合治疗冠心病患者高胆固醇血症的长期安全性
Br Heart J. 1995 Jul;74(1):14-7. doi: 10.1136/hrt.74.1.14.
5
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).4444例冠心病患者降胆固醇随机试验:斯堪的纳维亚辛伐他汀生存研究(4S)
Lancet. 1994 Nov 19;344(8934):1383-9.
6
Simvastatin therapy for hypercholesterolaemia in patients with coronary heart disease.
N Z Med J. 1990 Feb 14;103(883):41-3.
7
Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment.斯堪的纳维亚辛伐他汀生存研究(4S)中心肌梗死后发生主要冠状动脉事件的危险因素。预测风险对降胆固醇治疗益处的影响。
Eur Heart J. 2001 Jul;22(13):1119-27. doi: 10.1053/euhj.2000.2481.
8
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.降低血脂以降低冠状动脉疾病风险的指南:瑞舒伐他汀与阿托伐他汀、普伐他汀和辛伐他汀在实现降脂目标方面的比较。
Am J Cardiol. 2003 Mar 6;91(5A):11C-17C; discussion 17C-19C. doi: 10.1016/s0002-9149(03)00004-3.
9
Simvastatin compared to fluvastatin in the reduction of serum lipids and apolipoproteins in patients with ischaemic heart disease and moderate hypercholesterolaemia.辛伐他汀与氟伐他汀对缺血性心脏病合并中度高胆固醇血症患者血脂及载脂蛋白降低作用的比较。
Acta Cardiol. 1998;53(1):7-14.
10
Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.在MERCURY I试验中,瑞舒伐他汀与阿托伐他汀、辛伐他汀和普伐他汀在实现胆固醇目标及改善伴有或不伴有代谢综合征的高胆固醇血症患者血脂方面的比较。
Diabetes Obes Metab. 2005 Jul;7(4):430-8. doi: 10.1111/j.1463-1326.2004.00450.x.